SAPHIRA 1 topline shows competitive clinical results in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SAPHIRA 1 topline shows competitive clinical results in G551D patients
  • First potentiator after Kalydeco ®[1] to show comparable results in G551D patients
  • GLPG1837 was generally well tolerated when dosed up to 500 mg twice daily for 14 days
  • Statistically significant and dose dependent decreases in sweat chloride observed
  • Clinical validation of in vitro predictive platform

Webcast presentation tomorrow (21 Dec) at 15.00 CET/9 AM ET,  www.glpg.com , + 32 2 404 0659 , code 6588087

Mechelen, Belgium; 20 December 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) reports topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.

The SAPHIRA 1 trial included 26 patients with the G551D mutation in CFTR each receiving three sequential doses of GLPG1837. Of these, 25 patients were on stable Kalydeco treatment at screening and agreed to a one week washout prior to the start of dosing GLPG1837. One patient was naïve to Kalydeco. All subjects received GLPG1837 125 mg bid (twice-daily) for 7 days, immediately followed by 250 mg bid for 7 days and subsequently by 500 mg bid for 14 days. 

A statistically significant dose dependent decrease in sweat chloride concentration was observed. At the 500 mg bid dose, sweat chloride decreased from a mean value of 98 mmol/L at baseline to 66 mmol/L (p <0.0001). For those patients exceeding the predicted target concentration, sweat chloride changed from a mean value of 94 mmol/L at baseline to 52 mmol/L.

25 patients were on stable treatment with Kalydeco prior to this study. For these patients, mean percent predicted FEV1 (ppFEV1) levels were 74% at screening (prior to Kalydeco washout). The one week wash-out resulted in a 5.4% mean decrease in absolute ppFEV1. At the end of treatment with GLPG1837, the ppFEV1 levels returned to the Kalydeco pre-washout levels.

Overall GLPG1837 was well tolerated, with observed treatment emergent adverse events being predominantly mild or moderate, and typical for a CF patient population. One patient dropped out of the study due to an increase in non-cardiac creatine phosphokinase.

"The success of this trial is an important milestone in two regards; firstly, GLPG1837 has shown safety and significant efficacy as a novel CFTR potentiator. Secondly, it demonstrates that the CF community is committed to the further development of CFTR modulators despite the complexities related to evolving standards of care," commented Prof Jane Davies of the Royal Brompton & Harefield NHS Trust in London and principal investigator for SAPHIRA 1.

"The SAPHIRA 1 results show this is the first new potentiator since Kalydeco to demonstrate competitive results in patients harboring the G551D mutation. Galapagos has a suite of potentiators in development. Galapagos and AbbVie will further study the data before deciding which potentiator will be included in the triple combination," said Dr Piet Wigerinck, CSO of Galapagos. "The clinical validation of our in vitro systems reinforces our belief in our approach to get to a triple combination therapy."

Conference call and webcast presentation Galapagos will conduct a conference call and webcast open to the public tomorrow (21 December 2016) at 15:00 Central European Time (CET) or 9 AM ET. To participate in the conference call, please call one of the following numbers ten minutes prior to commencement:

CODE: 6588087

   
UK: +44 330 336 9105
Netherlands: +31 20 721 9251
France: + 33 1 76 77 22 74
Belgium: + 32 2 404 0659
USA: +1 719 325 4746
   

A question and answer session will follow the presentation of the results. Go to www.glpg.com to access the live audio webcast. The archived webcast will also be available for replay shortly after the close of the call.

About Galapagos Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises a pipeline of Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta , has approximately 480 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com .

Contacts

   
Elizabeth Goodwin  
VP IR & Corporate Communications  
+1 781 460 1784   Paul van der Horst Director IR & Business Development +31 6 53 725 199  
ir@glpg.com  

This press release contains inside information within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).

Forward-looking statements This release may contain forward-looking statements, including statements regarding the potential activity of GLPG1837, the anticipated timing of clinical studies with GLPG1837, the progression and results of such studies, and statements regarding a potential triple combination therapy. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs in cystic fibrosis may not support registration or further development of GLPG1837 due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for cystic fibrosis, AbbVie), and estimating the commercial potential of Galapagos' product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

[1] Kalydeco ® is marketed drug of Vertex Pharmaceuticals

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 122

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 491

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 307

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 20

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 75

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 58

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 14

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading

Top 5 Most Recently Viewed Articles

Genius Group Takes Center Stage at Major Investor Events

Updated Category News Views 214

Genius Group Highlights Major Sponsorships in 2025 Genius Group Limited (NYSE: GNS), an AI-driven education enterprise that prioritizes Bitcoin, has announced its participation in two pivotal investor summits. These events provide a significant platform for the company to engage with institutional investors and emphasize its innovative approach to digital assets. Engaging...

Continue Reading
Miami International Holdings Celebrates Robust Q3 Growth

Updated Category News Views 172

Miami International Holdings Reports Strong Financial Performance Miami International Holdings, Inc. (MIH) (NYSE: MIAX) has recently announced impressive financial outcomes for its third quarter, highlighting a remarkable growth trend. The financial data unveiled reflects the organization's ability to thrive in a highly competitive landscape. With a net revenue increase...

Continue Reading
Market Insights: Momo Crowd and GM's Tariff Burdens

Updated Category News Views 382

Understanding Momo Crowd Dynamics in Today's Market The stock market consistently reflects a myriad of influences, one of which is the behavior of retail investors, commonly referred to as the 'momo crowd.' Recent analyses indicate that the actions of these investors can significantly shape market trends, especially during times of heightened volatility. The Cautionary...

Continue Reading
Cathie Wood Praises Shopify: The Future of AI in Retail Awaits

Updated Category News Views 129

Cathie Wood's Enthusiastic Endorsement of Shopify ARK Invest, led by the visionary Cathie Wood, has recently expressed considerable confidence in Shopify Inc. SHOP. This faith stems from the company's forward-thinking approach toward artificial intelligence, particularly their dedicated focus on what they call 'agentic AI'. As the retail landscape evolves, many investors...

Continue Reading
Liftoff IPO: What’s the Real Play Behind the Curtain?

Updated Category News Views 244

Liftoff Mobile's been in the game since day one—on February 17, 2026, they dropped a bombshell, submitting their draft registration statement for an initial public offering (IPO) with the SEC. But hold your horses: nobody knows how many shares will float or what price range they’re angling for. That vagueness? Classic Wall Street move to stir up speculation while...

Continue Reading